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Abstract. QT interval prolongation typically assessed with dedicated clinical trials called
thorough QT/QTc (TQT) studies is used as surrogate to identify the proarrhythmic risk of
drugs albeit with criticism in terms of cost-effectiveness in establishing the actual risk of
torsade de pointes (TdP). Quantitative systems toxicology and safety (QSTS) models have
potential to quantitatively translate the in vitro cardiac safety data to clinical level including
simulation of TQT trials. Virtual TQT simulations have been exemplified with use of two
related drugs tolterodine and fesoterodine. The impact of bio-relevant concentration in
plasma versus estimated heart tissue exposure on predictions was also assessed. Tolterodine
and its therapeutically equipotent metabolite formed via CYP2D6 pathway, 5-HMT, inhibit
multiple cardiac ion currents (IKr, INa, ICaL). The QSTS model was able to accurately
simulate the QT prolongation at therapeutic and supra-therapeutic dose levels of tolterodine
well within 95% confidence interval limits of observed data. The model was able to predict
the QT prolongation difference between CYP2D6 extensive and poor metaboliser subject
groups at both dose levels thus confirming the ability of the model to account for
electrophysiologically active metabolite. The QSTS model was able to simulate the negligible
QT prolongation observed with fesoterodine establishing that the 5-HMT does not prolong
QT interval even though it is a blocker of hERG channel. With examples of TOL and FESO,
we demonstrated the utility of the QSTS approaches to simulate virtual TQT trials, which in
turn could complement and reduce the clinical studies or help optimise clinical trial designs.
KEY WORDS: arrhythmia; cardiac safety; Cardiac Safety Simulator; fesoterodine; hERG; thorough QT
trial; tolterodine; torsade de pointes.
INTRODUCTION
Adverse effect of drugs on cardiac electrophysiology
especially incidents of torsade de pointes (TdP) is one of the
most prominent cause of withdrawal of several marketed
drugs towards the end of the twentieth century and
beginning of the 21st (1–4). Occurrence of TdP is typically
a rare adverse event; however, the consequences could be
life-threatening hence there is more regulatory concern for
safe use of drugs. The risk of TdP has been ascribed for
drugs spanning wider therapeutic areas, other than cardio-
vascular drugs (5); hence, it has become important to assess
the TdP risk for any new medicine. As TdP is a rare and
multi-factorial event, it is very difficult to predict. A drug
that is well tolerated in most patients can cause TdP in a
particular individual under certain clinical situations, e.g.
disease or co-medications or electrolyte imbalance (6).
Thus, actual incidence of TdP can be a result of multiple
clinical risk factors other than drug’s ability to perturb
cardiac electrophysiology making it rare and challenging to
predict its risk precisely. However, as TdP is a type of
polymorphic ventricular tachycardia or arrhythmia, there is
an association between prolongation of QT interval of
electrocardiogram (ECG) and TdP. A drug that can prolong
QT interval could potentially cause TdP. Hence, QT interval
prolongation by the drug is considered an acceptable
biomarker of TdP risk albeit with some criticism (7). In
2006, the ICH issued a first formal guidance (E14) in this
regard—BThe Clinical Evaluation of QT/QTc Interval
Prolongation and Proarrhythmic Potential for Non-
Antiarrhythmic Drugs^ (8). QTc is the QT interval
corrected for the heart rate variations by suitable formulae.
The major aspect of the guidance was the thorough QT/QTc
(TQT) study that is a dedicated and well-controlled clinical
1 Simcyp Division, Certara UK Limited, Level 2-Acero, 1 Concourse
Way, Sheffield, S1 2BJ, UK.
2 Unit of Pharmacoepidemiology and Pharmacoeconomics, Faculty of
Pharmacy, Jagiellonian University Medical College, Krakow,
Poland.
3 To whom correspondence should be addressed. (e–mail:
Nikunjkumar.Patel@certara.com)
The AAPS Journal (2018) 20: 83
DOI: 10.1208/s12248-018-0244-3
1550-7416/18/0500-0001/0 # 2018 The Author(s)
trial to quantify the propensity of drug to prolong QT/QTc
at therapeutic and supra-therapeutic dose levels as com-
pared to positive control. The cause of concern in TQT trial
is the QT prolongation exceeding 5 ms determined by
whether the upper boundary of the 95% confidence interval
around the mean effect on the QT interval is larger than
10 ms. QT interval varies significantly larger than 5 ms
naturally during the day, due to meal effect, gender and
hormonal effects and other factors hence to detect such a
small difference in a parameter (QT interval) with inher-
ently high basal variability, the study is typically well
controlled for baseline, placebo and time of day
(circadian) effects and includes positive control (typically
moxifloxacin). QT varies with heart rate hence various
correction formulae are applied to correct QT for heart rate
changes (known as QTc) among which the Fridericia
method is widely used (9). E14 guidelines are adopted by
many regulatory agencies and TQT trials have become
routine in new drug approval process.
There are no drugs withdrawn from the market due to
TdP risk after introduction of TQT trials; however, there are
concerns that the optimal fail fast fail safe paradigm in recent
drug development programmes lead to unnecessary removal
of therapeutically promising molecules at early stage of
development due to perceived safety risk (10). There are
also doubts regarding the cost-effectiveness of the TQT trials
in identifying the TdP risk; therefore, alternative approaches
are being evaluated (11). Moreover, the number of reports of
TdP remains significant indicating there is a translational gap
in estimating the real-world TdP risk of new drugs (4). Thus,
translational tools that allow prediction of clinical cardiac risk
and clinical QT response are greatly needed (6,12). One such
set of tools are physiologically based, biophysically detailed
models of cardiac physiology that can characterise the
contributions of multiple ion channel inhibition on the
electrophysiology of human cardiomyocytes incorporated in
the physical model of ventricular wall as string of cells
arranged from inside to outside of ventricular wall. These
multi-scale quantitative systems toxicology and safety (QSTS)
models can bridge the translational gap in cardiac safety
assessment with the use of in vitro dynamic ion channel
inhibition data and expected exposure levels to simulate
subsequent effects on ECG profile in virtual patients, which
represent an array of physiologies expected in clinical
practice (13,14). Such QSTS approach allows mechanistic
in vitro to in vivo extrapolation (IVIVE) of preclinical cardiac
safety assessment to clinical cardiac safety risk and can aid in
bridging the translational gap in TdP risk assessment (15).
Recently, we have used the QSTS models to predict
quantitatively the QT prolongation effect of a drug influenc-
ing multiple cardiac ion channels with electrophysiologically
active metabolite(s) such as citalopram (12) and moxifloxacin,
drug widely used as positive control in TQT trials (6). More
of such examples will allow for more confidence and pave a
path towards establishing mechanistic simulations in bridging
the existing translational gap in preclinical to clinical
cardiotoxicity. Here, we report utilisation of such QSTS
platform, the Cardiac Safety Simulator (CSS) (14,16), that
combines a mechanistic electrophysiological model of human
left ventricular cardiomyocytes with the database of human
physiological, genotypic and demographic data for the
prediction of human QT prolongation, for tolterodine
(TOL) and its therapeutically equipotent metabolite 5-
hydroxymethyl tolterodine (5-HMT). Both TOL and 5-
HMT are known to interact with multiple cardiac ion channel
currents (ht tp : / /www.ema.europa.eu/docs /en_GB/
document_library/EPAR_-_Scientific_Discussion/human/
000723/WC500040181.pdf). As the CSS platform also allows
to propagate population variability in pharmacokinetics (drug
exposure) towards pharmacodynamics (cardiac activity), we
also simulated a virtual TQT study for therapeutic (2 mg) and
supra-therapeutic (4 mg) dose of tolterodine along with
moxifloxacin (MOXI) 400 mg given orally as a positive
control and compared the simulation results with reported
clinical TQT study results (17). In a separate virtual TQT
study (18), the cardiac effect of fesoterodine (FESO), an ester
pro-drug of 5-HMT (19), was simulated. Therapeutically
recommended (4 mg) and supra-therapeutic (28 mg) doses
of FESO were combined with 400 mg MOXI used as positive
control in this clinical TQT trial.
MATERIALS AND METHODS
Pharmacology of the Tested Drugs
5-HMT is formed by metabolism of TOL via cytochrome
P450 (CYP) 2D6 enzyme (17,20), which is known to have
genotypic and phenotypic differences in human populations
(21). 5-HMT itself is metabolised by predominantly via
CYP2D6 and CYP3A4 pathways with minor contribution of
renal excretion. The clinical TQT study (17) identified the
extensive metaboliser (EM) and poor metaboliser (PM)
phenotype status of subjects and reported the exposure levels
for both groups and the subsequent QT prolongation. Natural
frequency of PM phenotype in Caucasian population is
around 8% (Simcyp in-house meta-analysis data). However,
the clinical study recruited around 45% subjects with PM
status to include sufficient representation of PM group in the
studied cohort. We also simulated EM and PM groups with
similar number of subjects as clinical study and verified the
predictions with clinical data. The influence of exposure in
systemic circulation versus estimated exposure in heart tissue
was also studied in the current work.
Fesoterodine is an ester pro-drug of 5-HMT. FESO was
designed to produce therapeutically active metabolite (5-HMT)
of TOL avoiding the CYP2D6 polymorphism-related variability
in pharmacokinetics in exposure levels in patients because the
conversion of FESO to 5-HMT is driven by ubiquitous esterase
enzymes (19). FESO converts rapidly and almost completely to
5-HMT in systemic circulation as evident from the observation
that the FESO is almost undetectable in systemic circulation
after oral administration (18).
Clinical Pharmacokinetic and QT Prolongation Data
Tolterodine
Bio-relevant exposure levels of active chemical moieties
along with ion channel activity are required as input to the CSS
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system to predict the QT interval prolongation effect. Malhotra
et al. (17) have reported results from a thorough QT trial at
therapeutically recommended (2 mg BID) and supra-therapeutic
(4 mg BID) dose of TOL with 400 mg MOXI as positive control.
The steady-state (day 4) maximum plasma concentration
(Cmax,SS) for TOL and metabolite 5-HMT after 2- and 4-mg
BID dose levels for CYP2D6 EM and PM subject groups along
with Cmax,SS for MOXI treatment were obtained from Malhotra
et al. (17). Virtual subjects were generated based on the
demographic information (age, gender and body weight) pro-
vided in the clinical study based on bootstrapping method. The
population variability in drug exposure parameters (here,
Cmax,SS,TOL and Cmax,SS,5-HMT for both EM and PM groups) was
simulated using the bootstrappingmethod based on themean and
variance of population pharmacokinetics (PK) parameters re-
ported in the study. The population variability in PK was then
propagated into theCCS platform to predict theQT prolongation
for the virtual trial population. The placebo effect was simulated
as theQTprolongation responsewith zero drug concentration for
a given subject at given time point. Heart tissue to plasma
partition coefficient (Kheart:plasma) was estimated with ‘Method 3’
in Simcyp Simulator V16 (Certara UK Limited, Sheffield, UK)
where the ‘bottom-up’ predicted volume of distribution at steady
state (Vss) from physicochemical parameters of the chemical
moieties was calibrated with observed Vss for both TOL and 5-
MHTusing ‘Kp scalar’. ‘Kp scalar’ is a multiplier to the estimated
tissue:plasma partition coefficients from ‘Method 3’ of Simcyp
Simulator. The observed Vss for TOL was 1.66 L per kg of body
weight (22) while the predicted Vss from ‘Method 3’ from
physicochemical parameters was 2.8 L/kg. With ‘Kp scalar’ value
of 0.75, the predicted Vss matched well to the observed Vss. With
adjusted ‘Kp scalar’ to match the observed Vss, the estimated
Kheart:plasma for TOL was 0.48 and the fraction unbound in the
heart tissue (fu,Heart) from ‘Method 3’was 0.066. Similarly, the ‘Kp
scalar’ for ‘Method 3’ was adjusted to 0.46 to match the observed
Vss of 1.73 L/kg for 5-HMT (23). With adjusted ‘Kp scalar’ to
match the observedVss, the estimatedKheart:plasma for 5-HMTwas
2.93 and the fu,Heart from ‘Method 3’ was 0.088. These estimated
values of Kheart:plasma and the fu,Heart for TOL and 5-HMT were
used to calculate the total and unbound heart tissue concentration
of both moieties from the observed plasma concentration data.
Moxifloxacin
Daily dose of 400 mg MOXI was administered orally to
volunteers in positive control arm of the TQT trial and QT
prolongation was estimated on day 4. We have previously
developed a PBPK-QSTS model for MOXI (6). We used the
same PBPK model of MOXI and ran simulation for multiple
daily doses of 400 mg and calculated the maximum unbound
heart tissue exposure levels on day 4 and input to the CSS
platform to drive the QT response. The maximum QTc
prolongation was calculated from simulated study arm and
compared with the reported QTcF prolongation in the TQT
study report.
Fesoterodine
Malhotra et al. (18) have reported results from a
thorough QT trial of FESO at therapeutically recom-
mended (4 mg sustained release tablet once a day for
three days) and supra-therapeutic (28 mg, seven sustained
release tablets of 4 mg FESO given once a day for three
days) dose of FESO with 400 mg MOXI as positive
control. The steady-state (day 3) maximum plasma con-
centration (Cmax,SS) for active metabolite 5-HMT after 4-
and 28-mg dose levels were obtained from Malhotra et al.
(18). Similar to TOL, virtual subjects population variabil-
ity in drug exposure parameters (here, Cmax,SS,5-HMT) were
generated based on bootstrapping method. The population
variability in PK was then propagated into the CCS
platform to predict the QT prolongation for the virtual
trial population. The placebo effect was simulated as the
QT prolongation response with zero drug concentration
for a given subject at given time point. Simulations with
only unbound plasma concentration as operating concen-
tration were studied for FESO.
In Vitro/In Silico Cardiac Safety Data
TOL is known to inhibit at least three cardiac ion
currents namely IKr (rapid delayed rectifying current), INa
and ICaL (sodium and late calcium currents respectively)
that are important in cardiac electrophysiology (http://
www.ema.europa.eu/docs/en_GB/document_library/
EPAR_ - _ S c i e n t i fi c _D i s c u s s i o n / h uman / 0 0 0 7 2 3 /
WC500040181.pdf). Its metabolite, 5-HMT, is also known to
inhibit at least the same three cardiac ion channel currents
as the parent albeit with different potency (http://
www.ema.europa.eu/docs/en_GB/document_library/
EPAR_ - _ S c i e n t i fi c _D i s c u s s i o n / h uman / 0 0 0 7 2 3 /
WC500040181.pdf). Concentration of the ligands required
to inhibit 50% of the current of studied ion channel (IC50
values) of TOL and 5-HMT for IKr, INa and ICaL currents
are reported in Table I.
Simulation Methodology
CSS version 2.1 (Certara UK Limited, Sheffield, UK)
was used to perform simulations. The ten Tusscher 2006
model (24) of cardiomyocte electrophysiology imple-
mented in CSS platform was used to model drug effect
on ion channels at cell level. The CSS platform considers
the heterogeneities in ionic currents between endocardial,
midmyocardial and epicardial cells by one-dimensional
fibre (ventricular wall thickness) paced at the epicardial
side. The 50:30:20 distribution of the endo-, mid- and
epicardial cells was used to compose the ventricular wall
thickness together with the diffusion coefficient equal to
0.0016 cm2/ms. The forward Euler method was used to
integrate model equations. First and last beats were
excluded from the simulated pseudoECG to provide
stable signal. An ECG trace produced by the model is
termed pseudoECG as it misses the P wave because the
model only accounts for the ventricular cell wall. A space
step and a time step were set to Δx = 0.01 mm and Δt =
0.01 ms, and total simulation time was set to 10,000 ms in
all cases. To account for the drug-triggered ionic currents
modifications, the specific equation describing current of
interest was multiplied by the inhibition factor accordingly
to the in vitro values provided by the literature search
describing the concentration-dependent ionic current
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inhibition. The inhibition factor was calculated with the
use of the Hill equation [Eq. 1].
Inhibition factor ¼ 1
1þ IC50=drug concentrationð Þn ð1Þ
where IC50 is the concentration responsible for the 50%
inhibition of the ionic current, n is the Hill equation
parameter, drug concentration is the active drug concentra-
tion [μM].
The population variability of other physiological param-
eters was mimicked by applying the virtual population
generator as described previously (25,26). The circadian heart
rate variability model has recently been incorporated into the
CSS system to enable assessment of circadian variations in
heart rate on the estimate of QT prolongation (27). To
account for the circadian plasma ions, a variability model
describing the gender-dependent diurnal fluctuation of the
three main ions (Ca2+, K+ and Na+) has been applied (28,29).
CSS allows simulation of clinical scenarios inclusive of effect
of circadian variation on predicted QT which can aid in
understanding potential between subjects and within subject
variations in QT response prior to costly and time-intensive
TQT clinical studies.
Placebo and heart rate-corrected QT interval prolonga-
tion (ΔΔQTc) was calculated from simulated data and
compared with reported values from clinical TQT trials. The
CSS platform already outputs the heart rate-corrected QT
interval by Fridericia formulae (QTcF). The simulations
included placebo (null) simulation, where additional simula-
tion was run with zero drug concentration for each individual
and at each simulated time point. ΔΔQTcF was calculated for
simulation results by subtracting the QTcF in absence of drug
from the value of QTcF in presence of drug.
RESULTS
Tolterodine
The clinically observed ΔΔQTcF (ms) at 2- and 4-mg
BID dose levels for population of 48 subjects was reported in
study by Malhotra et al. (17). Sweeney et al. (30) have
analysed the TQT trial clinical data using population PKPD
model to estimate the population mean of EM and PM
groups. The simulated QT prolongation data of 48 subjects,
separated by EM (N = 27) and PM (N = 21) groups, are
reported along with clinical ΔΔQTcF data for 2- and 4-mg
dose groups in Fig. 1a, b, respectively. The simulations were
run using four concentration levels to study the most bio-
relevant exposure surrogate to explain the observed ΔΔQTcF
data—(i) total plasma concentration; (ii) unbound plasma
concentration; (iii) total heart tissue concentration and (iv)
unbound heart tissue concentration. The results clearly
showed that the total heart tissue and total plasma concen-
trations over-estimated the ΔΔQTcF. There was no signifi-
cant difference between the predictions using the unbound
plasma and unbound heart tissue concentrations mainly
because the estimated partition coefficient for TOL between
heart tissue and plasma is approximately 0.45 and the fuHeart
of 0.066; thus, unbound heart tissue and plasma exposures
were similar. The predictions using the unbound plasma and
unbound heart tissue exposure levels were closest to clinically
observed ΔΔQTcF for both EM and PM groups and at both
dose levels (Fig. 1).
Figure 2 shows the comparative ΔΔQTcF prolongation
from simulated and clinical TQT trial results for therapeutic
and supra-therapeutic dose levels of TOL along with positive
control MOXI. The vertical error bar indicates the 95%
confidence interval around the mean ΔΔQTcF from the
clinical study and simulated population.
The concentration-ΔΔQTcF relationships for both dose
levels and by EM and PM groups are provided in Fig. 3.
Figure 3a, b shows the relationship for 2- and 4-mg BID dose
levels while Fig. 3c, d shows the relationship for EM and PM
groups, respectively. There is no considerable difference in
slopes of concentration-ΔΔQTcF relationship, which ranged
from 10 to 15 ms/ng/mL.
Figure 3 clearly shows poor relationship between 5-HMT
concentration and ΔΔQTcF indicating that the metabolite 5-
HMT had negligible contribution to the predicted QT
prolongation while the TOL concentration was linearly and
positively correlated with the ΔΔQTcF. EM subjects showed
larger values of slope than the PM subjects (approx. 5 ms/ng/
mL larger) while the lower dose had slightly higher slope than
the higher dose level.
Fesoterodine
The clinically observed ΔΔQTcF (ms) at 4- and 28-mg
FESO dose levels were reported in study by Malhotra et al.
(18). Figure 4 shows comparative values of ΔΔQTcF (ms)
Table I. Cardiac ion channel inhibition data used in simulations and its source
Moiety IC50 in μM (Hill equation coefficient
$)
IKr INa ICaL Reference
TOL 0.011 (1) 4.85 (1) 560 (1)* (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/
000723/WC500040181.pdf)
5 -
HMT
0.39 (1) 17.25 (1) 560 (1)^ (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/
000723/WC500040181.pdf)
*Calculated IC50 within the CSS platform based on %inhibition versus concentration profile reported in reference (17% inhibition at 15 μM
concentration of TOL); ^calculated IC50 within the CSS platform based on %inhibition versus concentration profile reported in reference
(18% inhibition at 15 μM concentration of TOL); $Hill coefficient was not reported in the study hence assumed to be 1 in all cases
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from simulated trial and observed data on day 3 at both dose
levels.
The model predicted the QT interval prolongation really
well at lower dose level of 4 mg; however, the clinical results
showed no change or slight shortening of QTcF interval (−
0.1 ms) at higher dose of 28 mg while the model predicted
small QT prolongation (3 ms). The simulated variability was
much smaller than that observed in the clinical trial and the
simulated results are within the 95% confidence interval
reported in the clinical study (also showed as vertical error
bars in Fig. 4). Thus, the results based only on in vitro cardiac
safety input data is in good agreement with clinical TQT trial.
DISCUSSION
TOL, an antimuscarinic agent used for the treatment of
overactive bladder, has an equipotent metabolite 5-HMT.
TOL is found to be a potent inhibitor of hERG channel while
the metabolite 5-HMT is a magnitude less potent in inhibiting
hERG. Both TOL and 5-HMT inhibit late calcium channel
although with very low potency. The unbound fraction of
TOL and 5-HMT in plasma is around 3.7 and 36%,
respectively (17). Therefore, even though the exposure levels
of TOL are many-fold higher in CYP2D6 PM subjects, the
effective free plasma exposure of net therapeutically active
moieties are comparable in EM and PM groups negating the
need for dose adjustment for PM group. However, the cardiac
safety profile could be different due to significant difference
in potency of TOL and 5-HMT in inhibiting the hERG
channel. As the TOL is > 10-fold more potent hERG
inhibitor than 5-HMT, a considerably higher QT prolongation
is expected in PM subject group. However, simulated results
as well as clinical observations indicate only a small increase
in QT prolongation in PM subjects as compared to EM
subjects mainly due to much higher binding of TOL to plasma
proteins moderating the increase in total plasma
Fig. 1. Observed and simulated ΔΔQTcF (ms) for a 2-mg BID and b 4-mg BID dose levels.
Blue solid bars represent observed data, orange diagonal striped bars represent the simulated
data with unbound plasma concentration as operating concentration, yellow horizontal striped
bars represent simulated data with unbound heart tissue concentration as operating
concentration, purple brick patterned bars represent the simulated data with total plasma
concentration as operating concentration, green vertical striped bars represent simulated data
with total heart tissue concentration as operating concentration. Observed data for extensive
and poor metabolizer groups was obtained by population pharmacokinetic-pharmacodynamic
(popPKPD) modelling of clinical data. The black thin error bars represent the 95% confidence
interval around the mean value
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Fig. 2. Clinically observed and simulated ΔΔQTcF (ms) at therapeutic and supra-therapeutic dose
levels of tolterodine along with positive control drug moxifloxacin for thorough QT trial of
tolterodine. Clinical ΔΔQTcF calculated from machine-read electrocardiogram is represented with
solid blue bar, clinical ΔΔQTcF calculated from manual-read electrocardiogram is represented with
vertically striped yellow bar, and simulated ΔΔQTcF is represented with horizontally striped green
bar. The black thin error bars represent the 95% confidence interval around the mean value
Fig. 3. The concentration-ΔΔQTcF relationships for tolterodine and metabolite 5-hydroxymethytolterodine after
administration of 2-mg BID dose (a) and 4-mg BID dose (b) of tolterodine and for extensive metabolizer population
group (c) and poor metabolizer population groups (d)
83 Page 6 of 9 The AAPS Journal (2018) 20: 83
concentration in PM subjects. Natural frequency of CYP2D6
PM polymorphism in normal population is around 8%;
however, the clinical study, and hence the simulated trial,
was enriched with higher proportion of PM (45%) subjects to
sufficiently represent the high-risk PM group subjects. The
simulation results indicated that the QSTS model accurately
predicted the clinical QT prolongation not only for therapeu-
tic and supra-therapeutic dose levels but also was able to
differentiate the effect of EM and PM exposure levels on QT
prolongation. It is also important to note that the clinically
observed QT interval prolongation estimated with machine-
read ECG is systematically lower than the manual-read ECG
(Fig. 2). When the QSTS model is assessed in terms of its
predictive performance for such smaller values of QT interval
prolongation, it becomes important to understand the vari-
ability and uncertainty associated with the clinical data and/or
the measurement technique. There were considerable differ-
ences in QT prolongation from clinical study noted between
manually read and machine ECG; hence, both machine-read
and manual-read values were provided along with predicted
results (Fig. 2). For MOXI arm, the simulated results were
within the reported 90% confidence interval of clinical data
from machine-read ECG while higher than the reported
value with manually read ECG (17). We have previously
shown that there exists inter-study variability in QT interval
prolongation after 400 mg MOXI once-daily (OD) treatment
due to multiple of study design factors such as encapsulation
of tablet for purpose of blinding and manufacturer of the
formulation, etc. (6). We have shown there that the prediction
for MOXI was reasonably good at much wider pooled clinical
data set from six independent studies; thus, here, we consider
the prediction for MOXI positive arm acceptable. For TOL
2 mg BID as well as 4 mg BID, the simulated results were
well within 95% confidence interval of clinically reported
values from both machine-read and manual-read ECG
results. There are no animal or human studies reporting the
heart tissue exposure of TOL or 5-HMT; hence, the simulated
heart tissue exposure cannot be fully verified. We already
discussed at length the issues and uncertainties around the
bio-relevant exposure levels driving the cardiac response and
limited knowledge in public literature. We previously studied
the impact of model selection on MOXI, for example, the
O’Hara Rudy 2011 model (31) tends to predict larger QT
prolongation than the ten Tusscher 2006 model (24) for the
same input parameters (6); however, well-defined systematic
studies are needed to analyse such model comparison at
single cell level (action potential duration) as well as
ventricular wall level (QT prolongation) simulations to
provide further recommendations. More experimental data
at both in vitro and in vivo level and collaborative research
initiatives are required to complement QSTS modelling
results to test or establish hypotheses and move the field of
cardiac risk assessment forward.
Another important measure to assess the predictive
performance of the QSTS model would be to compare its
ability to simulate the effect (ΔΔQTcF) versus exposure
(drug concentration) profile. The slope of simulated
ΔΔQTcF-concentration relationship (10–15 ms/ng/mL) was
very similar to that reported from clinical data analysis
(population mean point estimate of 13.4 ms/ng/mL) for
unbound plasma concentration. Moreover, the QSTS model
showed no considerable difference in EM and PM groups
similar to the observation made from clinical data analysis by
Sweeney et al. (30). The contribution of metabolite 5-HMT
in QT prolongation was negligible as evident from no
correlation between 5-HMT concentration and QT prolon-
gation at both dose levels and for both EM and PM groups.
This observation from the simulated results can also be
verified with another TQT study report for FESO, the ester
pro-drug of 5-HMT. Clinical TQT trial of FESO with 4-mg
Fig. 4. Clinically observed and simulated ΔΔQTcF (ms) at therapeutic (4 mg) and supra-
therapeutic dose (28 mg) levels of fesoterodine in thorough QT trial. Clinically observed ΔΔQTcF
is represented with solid blue bar and simulated ΔΔQTcF is represented with horizontally striped
green bar. The black thin error bars represent the 95% confidence interval around the mean value
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and 28-mg dose resulted in negligible QT prolongation or
slightly shorter QT prolongation as compared to placebo.
The simulations predicted similarly low to negligible QT
prolongation at both dose levels of FESO. This clearly
establishes the outcome of simulation results from TOL
simulation that the 5-HMT does not prolong QT interval
even though it inhibits hERG channel. Ability to inhibit the
calcium channel could explain the slight shortening of the
QT interval in clinical TQT trial especially at higher dose
level (28 mg FESO) because the potency of 5-HMT to inhibit
the calcium channel is very low (Table I); thus, measurable
inhibition of calcium current can only be achieved at higher
exposure levels. Simulations, although recovered the ob-
served QT prolongation range of both dose levels really well,
could not mimic the QT shortening trend with dose.
Although not statistically significant, the clinical data showed
slightly lower QT prolongation at higher dose of FESO than
at lower dose. This could be due to fact that the IC50 value
for calcium channel inhibition was not available as the
maximum concentrations studied in vitro lead to around
17% inhibition of calcium current thus making it difficult to
derive accurate IC50 value. More accurate IC50 value for
calcium channel inhibition may allow the QSTS model to
recover the QT shortening effect at higher exposure levels.
The potency of TOL and 5-HMT is similar in inhibiting the
calcium current based on limited data available from
literature (http: / /www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Scientific_Discussion/human/
000723/WC500040181.pdf). As observed with lower slope of
ΔΔQTcF-concentration profile at higher dose (4 mg) com-
pared to the slope at lower dose (2 mg) in Fig. 3, the QSTS
model was able to estimate the trend of reduction in QT
prolongation effect at higher dose levels based on limited
input data for calcium channel inhibition. Thus, the success
of the QSTS model to predict the clinical QT interval
modification by drug strongly depends on quality and
accuracy of input data to the IVIVE methodology.
We showed previously that the metabolites of citalopram
were very important in predicting the QT prolongation
profile of citalopram (12); however, here, the metabolite 5-
HMT did not contribute to QT prolongation after TOL
treatment even though 5-HMT was a moderate hERG
channel blocker. Thus, QSTS approaches also allow testing
of various hypotheses such as the impact of metabolite on
safety and tolerability of the drug treatment. QSTS models
can be applied at early discovery levels as the models can be
fed with chemical structure to predict the QT prolongation
with use of quantitative structure activity relationship
(QSAR) techniques. As the drug progresses in the develop-
ment, the model can be enriched with better quality input
data, and the virtual TQT trials can be simulated when
sufficient knowledge on the PK of drug and metabolites
becomes available along with in vitro cardiac safety assess-
ment profiles, as it was presented in the current study. Once
sufficiently verified, such QSTS models can also be used to
refine and optimise the clinical study designs.
CONCLUSIONS
With examples of TOL and FESO, we demonstrated the
utility of the QSTS approaches to bridge the translational gap
in cardiac safety assessment and simulate virtual TQT trials.
Such simulations could complement and reduce the clinical
studies or help optimise clinical trial designs. Such QSTS
approaches can also help build and test hypothesis such as
assessing the role of unbound versus total plasma concentra-
tion or assessing the contribution of electrophysiologically
active metabolite and allow understanding impact of popula-
tion variability such as genetic polymorphism on the cardiac
safety profile of drugs. Population-based QSTS models could
also help address late-stage development questions such as
understanding the impact of metabolic drug-drug interactions
on cardiac safety risk and identify the high-risk clinical
situations for potential TdP. Adoption of such QSTS model-
ling strategies from early stages of drug discovery and
development and enrichment of model and information along
with drug product life cycle could allow bridging translational
gap in clinical cardiac safety assessment. More case examples
of drugs with varying PK and electrophysiological profiles are
needed to build confidence in such strategy for implementa-
tion in drug development and regulatory decision-making.
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